Equities Analysts Offer Predictions for FATE FY2025 Earnings

Fate Therapeutics, Inc. (NASDAQ:FATE) – Analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for Fate Therapeutics in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst L. Watsek forecasts that the biopharmaceutical company will earn ($1.67) per share for the year. The consensus estimate for Fate Therapeutics’ current full-year earnings is ($1.63) per share.

Fate Therapeutics (NASDAQ:FATE) last posted its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.02. Fate Therapeutics had a negative return on equity of 45.88% and a negative net margin of 1,325.43%. The business had revenue of $3.07 million for the quarter, compared to the consensus estimate of $0.88 million.

Other equities analysts also recently issued research reports about the company. Wedbush reiterated a “neutral” rating and issued a $5.00 price objective on shares of Fate Therapeutics in a research note on Tuesday, November 12th. Bank of America upgraded Fate Therapeutics from an “underperform” rating to a “neutral” rating in a research report on Monday, November 18th. Finally, Needham & Company LLC restated a “hold” rating on shares of Fate Therapeutics in a research report on Tuesday, November 19th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $6.75.

Fate Therapeutics Trading Up 1.5 %

Fate Therapeutics stock opened at $1.34 on Wednesday. Fate Therapeutics has a 12 month low of $1.04 and a 12 month high of $8.83. The business’s 50 day simple moving average is $1.96 and its 200 day simple moving average is $3.01. The company has a market cap of $152.61 million, a price-to-earnings ratio of -0.81 and a beta of 2.02.

Hedge Funds Weigh In On Fate Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in FATE. Deerfield Management Company L.P. Series C grew its position in shares of Fate Therapeutics by 62.3% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 3,555,871 shares of the biopharmaceutical company’s stock worth $11,663,000 after buying an additional 1,365,463 shares in the last quarter. Dimensional Fund Advisors LP grew its position in shares of Fate Therapeutics by 100.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,130,280 shares of the biopharmaceutical company’s stock worth $6,987,000 after buying an additional 1,067,101 shares in the last quarter. Renaissance Technologies LLC bought a new position in shares of Fate Therapeutics during the 2nd quarter worth $1,799,000. Perceptive Advisors LLC bought a new position in shares of Fate Therapeutics during the 2nd quarter worth $1,133,000. Finally, Barclays PLC grew its position in shares of Fate Therapeutics by 245.3% during the 3rd quarter. Barclays PLC now owns 424,277 shares of the biopharmaceutical company’s stock worth $1,485,000 after buying an additional 301,389 shares in the last quarter. Institutional investors own 97.54% of the company’s stock.

Insiders Place Their Bets

In related news, Director Redmile Group, Llc purchased 397,964 shares of the firm’s stock in a transaction that occurred on Friday, December 20th. The shares were bought at an average price of $1.68 per share, for a total transaction of $668,579.52. Following the acquisition, the director now owns 12,884,277 shares of the company’s stock, valued at approximately $21,645,585.36. This represents a 3.19 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 5.00% of the stock is currently owned by corporate insiders.

Fate Therapeutics Company Profile

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.